Advanced systemic mastocytosis: The impact of KIT mutations in diagnosis, treatment, and progression

European Journal of Haematology

Volumn 90, Issue 2, 2013, Pages 89-98

  Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Advanced systemic mastocytosis; Aggressive systemic mastocytosis; KIT; Response criteria; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; DASATINIB; HYDROXYUREA; IMATINIB; MASITINIB; MIDOSTAURIN; NILOTINIB; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

AGGRESSIVE SYSTEMIC MASTOCYTOSIS; ANEMIA; BODY WEIGHT; CONFORMATIONAL TRANSITION; DIARRHEA; DISEASE COURSE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; GENE MUTATION; HUMAN; INDOLENT SYSTEMIC MASTOCYTOSIS; MAST CELL LEUKEMIA; MASTOCYTOSIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PRURITUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; SYSTEMIC MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS ASSOCIATED WITH CLONAL HEMATOLOGIC NON MAST CELL LINEAGE DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

DRUG DELIVERY SYSTEMS; ENZYME ACTIVATION; HUMANS; LEUKEMIA, MAST-CELL; MAST CELLS; MUTATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84872762495     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12043     Document Type: Review

References (68)

1. Pardanani A. Systemic mastocytosis in adults: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:401-11.
2. Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology 2007;74:121-32.
3. Bulat V, Mihic LL, Situm M, Buljan M, Blajic I, Pusic J. Most common clinical presentations of cutaneous mastocytosis. Acta Clin Croat 2009;48:59-64.
4. Ozdemir D, Dagdelen S, Erbas T. Systemic mastocytosis. Am J Med Sci 2011;342:409-15.
5. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:5727-36.
6. Pardanani A, Lim K, Lasho TL, Finke C, McClure RF, Li C, Tefferi A. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009;114:3769-72.
7. Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, Bennett JM, Metcalfe DD. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003;27:635-41.
8. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 2004;61:2535-48.
9. Lim KH, Pardanani A, Tefferi A. KIT and mastocytosis. Acta Haematol 2008;119:194-8.
10. Lemmon MA, Pinchasi D, Zhou M, Lax I, Schlessinger J. Kit receptor dimerization is driven by bivalent binding of stem cell factor. J Biol Chem 1997;272:6311-7.
11. Amon U, Hartmann K, Horny HP, Nowak A. Mastocytosis - an update. J Dtsch Dermatol Ges 2010;8:695-711.
12. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741-4.
13. Horny HP. Mastocytosis: an unusual clonal disorder of bone marrow-derived hematopoietic progenitor cells. Am J Clin Pathol 2009;132:438-47.
14. Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 2009;6:627-37.
15. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-72.
16. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009;124:514-21.
17. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-53.
18. Pardanani A, Tefferi A. A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol 2010;84:371-8.
19. Valent P, Arock M, Akin C, et al. The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). Blood 2010;116:850-1.
20. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009;84:790-4.
21. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
22. Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003;31:686-92.
23. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A. Imatinib for systemic mast-cell disease. Lancet 2003;362:535-6.
24. Pagano L, Valentini CG, Caira M, et al. Advanced mast cell disease: an Italian Hematological Multicenter experience. Int J Hematol 2008;88:483-8.
25. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, Cross NC, Cavenagh JD. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30:373-8.
26. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103:3222-5.
27. Novartis Pharmaceuticals Corporation. Imatinib (Gleevec) Package Insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2012.
28. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
29. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093-6.
30. Alvarez-Twose I, Gonzalez P, Morgado JM, Jara-Acevedo M, Sanchez-Munoz L, Matito A, Mollejo M, Orfao A, Escribano L. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. J Clin Oncol 2012;30:e126-9.
31. Novartis Pharma AG. Nilotinib (Tasigna) Package Insert. Stein, Switzerland: Novartis Pharma AG, 2012.
32. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M, Fabbro D. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010;1804:445-53.
33. von Bubnoff N, Gorantla SH, Kancha RK, Lordick F, Peschel C, Duyster J. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 2005;19:1670-1.
34. Verstovsek S, Akin C, Manshouri T, Quintas-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 2006;30:1365-70.
35. Hochhaus A, Ottmann OG, Lauber S, Hughes T, Verhoef G, Schwarer AP, Gratwohl A, Rafferty T, Resta D, Gattermann N. A phase II study of nilotinib, a novel inhibitor of c-Kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis. Blood 2006;108:Abstract 2703.
36. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9.
37. Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol 2007;18:vi42-6.
38. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006;108:286-91.
39. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008;14:3906-15.
40. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
41. Purtill D, Cooney J, Sinniah R, Carnley B, Cull G, Augustson B, Cannell P. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol 2008;80:456-8.
42. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE 2009;4:e7258.
43. Paul C, Sans B, Suarez F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 2010;85:921-5.
44. Georgin-Lavialle S, Lhermitte L, Suarez F, et al. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to Masitinib, a c-Kit tyrosine kinase inhibitor. Eur J Haematol 2012;89:47-52.
45. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42.
46. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28.
47. Gotlib J, DeAngelo DJ, George TI, Corless CL, Linder A, Langford C, Dutreix C, Gross S, Nikolova Z, Graubert T. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. Blood 2010;116:Abstract 316.
48. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006;107:752-9.
49. Knapper S, Cullis J, Drummond MW, Evely R, Everington T, Hoyle C, McLintock L, Poynton C, Radia D. Midostaurin a multi-targeted oral kinase inhibitor in systemic mastocytosis: report of an open-label compassionate use program in the United Kingdom. Blood 2011;118:Abstract 5145.
50. Gotlib J, Kluin-Nelemans HC, George TI, et al. KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial. Blood 2012;120:Abstract 799.
51. Ustun C, DeRemer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011;35:1143-52.
52. Pardanani A. Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta Haematol 2005;114:41-51.
53. Li CY, Baek JY. Mastocytosis and fibrosis: role of cytokines. Int Arch Allergy Immunol 2002;127:123-6.
54. Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, Olivares N, Carter M, Maric D, Robyn J, Metcalfe DD. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011;96:459-63.
55. Gleixner KV, Blatt K, Peter B, Hadzijusufovic E, Valent P. Ponatinib exerts growth-inhibitory effects on neoplastic mast cells and synergizes with midostaurin in producing growth arrest and apoptosis. Blood 2011;118:Abstract 3497.
56. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007;138:12-30.
57. Tang X, Boxer M, Drummond A, Ogston P, Hodgins M, Burden AD. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet 2004;41:e88.
58. Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010;130:804-15.
59. Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, Heitjan D, Ma Y. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999;96:1609-14.
60. Pullarkat VA, Bueso-Ramos C, Lai R, Kroft S, Wilson CS, Pullarkat ST, Bu X, Thein M, Lee M, Brynes RK. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 2003;73:12-7.
61. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312-4.
62. Pignon JM, Giraudier S, Duquesnoy P, Jouault H, Imbert M, Vainchenker W, Vernant JP, Tulliez M. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997;96:374-6.
63. Wasag B, Niedoszytko M, Piskorz A, Lange M, Renke J, Jassem E, Biernat W, Debiec-Rychter M, Limon J. Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol 2011;39:859-65.e2.
64. Sotlar K, Escribano L, Landt O, Mohrle S, Herrero S, Torrelo A, Lass U, Horny HP, Bultmann B. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003;162:737-46.
65. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-44.
66. Nakagomi N, Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 2007;87:365-71.
67. Gotlib J, Kluin-Nelemans H, Mauro M, et al. A global, phase II, single-arm, open-label study to determine the efficacy of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without an associated hematologic clonal nonmast cell lineage disease (AHNMD). J Clin Oncol 2011;29:Abstract TPS200.
68. Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 2010;17:125-32.